Analysis of splice‐site mutations of the α‐galactosidase A gene in Fabry disease
- 3 June 2003
- journal article
- Published by Wiley in Clinical Genetics
- Vol. 63 (6), 476-482
- https://doi.org/10.1034/j.1399-0004.2003.00077.x
Abstract
Fabry disease is an X-linked disease caused by a defective lysosomal enzyme, alpha-galactosidase A, and characterized by skin lesions and multiorgan involvement, including kidney, heart, and the central nervous system. Currently more than 200 genotypes have been identified, including several aberrant splicing. However, most of the mutation analyses were performed using genomic sequencing only, and therefore some of the splicing mutations were misclassified as missense mutations. In order to predict the splicing event caused by each mutation, we conducted a literature search for all published mutations located near the splice sites, including exonic point mutations, and performed a splice-site score (SSS) analysis. The literature search identified 13 donor-site mutations, including four exonic mutations (S65T, D183S, K213N, and M267I), located at the end of exons 1, 3, 4, and 5, respectively, six acceptor-site mutations, and one new exon creation. All mutated splice sites, except for the one associated with the new exon creation, had a lower SSS than their respective natural sites. Cryptic or newly created sites were identified with SSS from 0.09 to 1.0. The predictions, based on SSS analysis, are in agreement with all six mutations with known cDNA sequence from the literature, including five mutations with exon skipping and one mutation with creation of a new acceptor site. For the S65T genotype, we performed reverse transcription-polymerase chain reaction (RT-PCR) analysis using RNA isolated from the whole-blood sample. We verified that a weak cryptic site (SSS = 0.09) 14 nucleotides downstream was activated and resulted in an insertion of 14 bp and a frameshift stop at codon 106. This change is more consistent with the clinical presentation of the patient, the classical Fabry disease, than the amino acid substitution (S65T), which does not affect the enzyme function. In conclusion, the SSS analysis is very useful for predicting splicing events and genotype/phenotype correlation in Fabry disease. As different mechanisms may be involved in pre-mRNA splicing, it is important to obtain cDNA sequencing for molecular diagnosis.Keywords
This publication has 26 references indexed in Scilit:
- A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genesNature Genetics, 2001
- Exhaustive mutation analysis of theNF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defectsHuman Mutation, 2000
- Identification of a novel point mutation (S65T) in α-galactosidase A gene in Chinese patients with Fabry diseaseHuman Mutation, 1998
- The Regulation of Splice-Site Selection, and Its Role in Human DiseaseAmerican Journal of Human Genetics, 1997
- ?-Galactosidase gene mutations in Fabry disease: heterogeneous expressions of mutant enzyme proteinsHuman Genetics, 1995
- Construction of a novel database containing aberrant splicing mutations of mammalian genesGene, 1994
- Detection of 8 new mutations in the α-galactosidase A gene in Fabry diseaseHuman Molecular Genetics, 1994
- Invariant exon skipping in the human α-galactosidase A pre-mRNA: A g+1 to t substitution in a 5′-splice site causing Fabry diseaseGenomics, 1992
- A 3′ splice site consensus sequence mutation in the intron 3 of the α-galactosidase a gene in a patient with Fabry diseaseJournal of Human Genetics, 1991
- Enzymatic Defect in Fabry's DiseaseNew England Journal of Medicine, 1967